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Abstract
Src tyrosine kinases are deregulated in numerous cancers and may favor tumorigenesis and tumor progression. We
previously described that Src activation in NIH-3T3 mouse fibroblasts promoted cell resistance to apoptosis. Indeed, Src was
found to accelerate the degradation of the pro-apoptotic BH3-only protein Bik and compromised Bax activation as well as
subsequent mitochondrial outer membrane permeabilization. The present study undertook a systems biomedicine
approach to design optimal anticancer therapeutic strategies using Src-transformed and parental fibroblasts as a biological
model. First, a mathematical model of Bik kinetics was designed and fitted to biological data. It guided further experimental
investigation that showed that Bik total amount remained constant during staurosporine exposure, and suggested that Bik
protein might undergo activation to induce apoptosis. Then, a mathematical model of the mitochondrial pathway of
apoptosis was designed and fitted to experimental results. It showed that Src inhibitors could circumvent resistance to
apoptosis in Src-transformed cells but gave no specific advantage to parental cells. In addition, it predicted that inhibitors of
Bcl-2 antiapoptotic proteins such as ABT-737 should not be used in this biological system in which apoptosis resistance
relied on the deficiency of an apoptosis accelerator but not on the overexpression of an apoptosis inhibitor, which was
experimentally verified. Finally, we designed theoretically optimal therapeutic strategies using the data-calibrated model. All
of them relied on the observed Bax overexpression in Src-transformed cells compared to parental fibroblasts. Indeed, they
all involved Bax downregulation such that Bax levels would still be high enough to induce apoptosis in Src-transformed cells
but not in parental ones. Efficacy of this counterintuitive therapeutic strategy was further experimentally validated. Thus,
the use of Bax inhibitors might be an unexpected way to specifically target cancer cells with deregulated Src tyrosine kinase
activity.
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Introduction
Protein tyrosine kinases of the Src family are involved in
multiple facets of cell physiology including survival, proliferation,
motility and adhesion [1]. Their deregulation has been described
in numerous malignancies such as colorectal, breast, melanoma,
prostate, lung or pancreatic cancers and is known to favor
tumorigenesis and tumor progression [2–4].
Modulation of apoptosis sensitivity by Src deregulation is more
controversial. We recently described that Src activation promotes
resistance to the mitochondrial pathway of apoptosis in mouse and
human cancer cell lines [5]. The molecular mechanism underlying
such resistance involved the accelerated degradation of the
proapoptotic BH3-only protein Bik. Indeed, in Src-transformed
NIH 3T3 mouse fibroblasts, Bik was found to be phosphorylated
by activated Erk1/2, which was followed by Bik subsequent
polyubiquitylation and proteasomal degradation [5]. Thus in Src-
transformed cells, Bik downregulation compromised Bax activa-
tion and mitochondrial outer membrane (MOM) permeabilization
upon an apoptotic stress [5].
That observation might be of importance since MOM
permeabilization is the key step that commits cells to apoptosis.
Indeed, MOM permeabilization leads to the irreversible release of
cytochrome c and other cytotoxic molecules from the mitochon-
drial inter-membrane space into the cytosol [6,7]. Once released,
cytochrome c induces the formation of the apoptosome complex,
which triggers caspase activation, these molecules being the main
executioners of the apoptotic program. MOM permeabilization is
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triggered by the insertion and oligomerization of the pro-apoptotic
effector Bax into the membrane [8–11]. Antiapoptotic proteins
such as Bcl-2 or Bcl-xL prevent this process, whereas pro-
apoptotic BH3-only proteins contribute to Bax activation [6,11–
16]. Using western blotting and specific shRNAs, the respective
contribution of the different Bcl-2 family members to the cell
response triggered by various death- inducing agents was assessed
in parental and Src-transformed NIH-3T3 fibroblasts [5].
Experimentally and mathematically investigating the cell
response to death-inducing agents might be of interest since it
has long been postulated that restoration of apoptosis might be an
effective way to selectively kill cancer cells. The rationale of this
assumption is that cancer cells need to counteract the pro-
apoptotic effect of oncogenes such as Myc or E2F-1 that stimulate
cell proliferation as well [17]. Moreover, Src deregulation has
specifically been associated with resistance to treatment in a
number of cancers [18,19]. Therefore, a critical clinical concern
lies in the design of therapeutic strategies that would circumvent
resistance to apoptosis of cells with deregulated Src activity. To
this end, several classes of therapeutic agents might be a priori
considered. Inhibitors of Src tyrosine kinases, such as dasatinib,
are currently widely used in the clinic [20–23]. Other anticancer
therapeutic strategies aim at restoring apoptosis in cancer cells
[24]. In particular, inhibitors of antiapoptotic proteins such as
ABT-737 or the Oblimersen Bcl-2 antisense oligodeoxyribonu-
cleotide are currently evaluated in clinical trials [25–28]. Apoptosis
may also be restored by increasing the expression of pro-apoptotic
proteins such as Bax, Bik or p53 [29–32].
Here we propose a systems biology approach for optimizing
potential anticancer therapeutic strategies using parental and Src-
transformed NIH 3T3 fibroblasts as a biological model. To this
end, molecular mathematical models of Bik kinetics and of the
mitochondrial pathway of apoptosis were built and fitted to
available experimental data. They guided further experimental
investigation in parental and Src-transformed cells which allowed
their refinement. Then, those models were used to generate
predictions which were validated by subsequent specifically-
designed experiments. Finally, we theoretically explored different
drug combinations involving the kinase inhibitor staurosporine,
Src inhibitors, and activators or inhibitors of the Bcl-2 protein
family, in order to design optimal anticancer strategies for this
biological system. Optimal strategies were defined as those which
maximized the efficacy on Src-transformed cells considered as
cancer cells under the constraint of toxicity remaining under a
tolerable threshold in parental cells.
Results
Bik kinetics in non-apoptotic conditions
We recently provided evidence that Bik, a BH3-only protein, is
a key regulator of apoptosis in the considered biological system [5].
Therefore we first built a mathematical model to investigate Bik
kinetics in non-apoptotic conditions. Bik concentration temporal
variations were assumed to result from two processes: protein
formation and protein polyubiquitylation, which eventually leads
to its degradation. Let us denote ½Bik and ½Bikub the intracellular
concentration of Bik and polyubiquitylated Bik proteins respec-
tively, expressed in nM.
Bik protein was assumed to be synthesized at a constant rate
kfBik in both Src-transformed and parental cells as suggested by
similar Bik mRNA level in both cell types [5]. Concerning Bik
ubiquitylation, we considered that it occurred either spontaneously
at the rate kubBik, or after Bik phosphorylation by activated Erk1/2
downstream of SRC activation, as demonstrated in Src-trans-
formed fibroblasts ([5], Figure 1). In those cells, this prior
Figure 1. Bik kinetics in non-apoptotic conditions. Bik proteins
are polyubiquitylated (Bikub) prior to their proteasomal degradation.
This ubiquitylation occurs spontaneously in parental NIH-3T3 cells and
is enhanced in Src-transformed cells through Src-dependent activation
of Erk1/2 kinases which accelerate Bik phosphorylation (Bikphos), thus
favoring its ubiquitylation.
doi:10.1371/journal.pcbi.1003011.g001
Author Summary
Personalizing medicine on a molecular basis has proven its
clinical benefits. The molecular study of the patient’s
tumor and healthy tissues allowed the identification of
determinant mutations and the subsequent optimization
of healthy and cancer cells specific response to treatments.
Here, we propose a combined mathematical and experi-
mental approach for the design of optimal therapeutics
strategies tailored to the patient molecular profile. As an in
vitro proof of concept, we used parental and Src-
transformed NIH-3T3 fibroblasts as a biological model.
Experimental study at a molecular level of those two cell
populations demonstrated differences in the gene expres-
sion of key-controllers of the mitochondrial pathway of
apoptosis thus suggesting potential therapeutic targets.
Molecular mathematical models were built and fitted to
existing experimental data. They guided further experi-
mental investigation of the kinetics of the mitochondrial
pathway of apoptosis which allowed their refinement.
Finally, optimization procedures were applied to those
data-calibrated models to determine theoretically optimal
therapeutic strategies that would maximize the anticancer
efficacy on Src-transformed cells under the constraint of a
maximal allowed toxicity on parental cells.
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phosphorylation increased Bik ubiquitylation rate and further
proteasomal degradation. This Src-dependent pathway was mod-
eled by Michaelis-Menten kinetics with parameters VSrc and KSrc.
In the model, we assumed that spontaneous and Src-mediated
ubiquitylation could occur in both transformed and parental cells.
Ubiquitin molecules were assumed to be in large excess compared
to Bik amount. Therefore ubiquitin concentration was considered as
constant and implicitly included in kdBik and VSrc.
Poly-ubiquitylated molecules Bikub were then assumed to be
degraded by the proteasome at a constant rate kdBik in both cell
types. kdBik was arbitrary set to 1 as it does not influence ½Bik
kinetics, and only acts on ½Bikub. The model of Bik kinetics can be
written as follows:
d½Bik
dt
~kfBik{kubBik½Bik{ VSrc½Bik
KSrcz½Bik ð1Þ
d½Bikub
dt
~kubBik½Bikz VSrc½Bik
KSrcz½Bik{kdBik½BikUb ð2Þ
Parameters were then estimated for parental and Src-trans-
formed cells by fitting experimental results on Bik protein
degradation in both cell types ([5], reprinted with permission in
Figure 2B). We assumed that the spontaneous phosphorylation
occurred at the same rate in parental and Src-transformed
fibroblasts and therefore looked for a unique kubBik. Parameters of
Src-dependent Bik degradation were denoted V
parental
Src and
K
parental
Src in parental cells and VSrc and KSrc in Src-transformed
3T3 cells. Inhibition of Src kinase activity by herbimycin was
experimentally monitored in Src-transformed cells (Figure 2A,
reprinted with permission from [5]). Herbimycin exposure
Figure 2. Estimating Bik degradation rates in control and Src-transformed cells. A Endogenous Bik level was compared with Src level and
Src kinase activity as monitored by Y416 phosphorylation in Src-transformed cells. v-Src kinase activity was inhibited either by herbimycin or by
incubation at 39.5uC. Src inhibition by herbimycin was quantified to 98%. Reprinted with permission from [5] B Bik degradation was monitored in
parental and Src-transformed cells. v-Src kinase activity was inhibited by herbimycin in transformed cells. Dots are experimental results reprinted from
[5]. Solid lines represent the best fit of Bik kinetics mathematical model (Equations 1 and 2). See Results for parameter values.
doi:10.1371/journal.pcbi.1003011.g002
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achieved a decrease of 98% in phosphorylated Y416 amount.
Therefore, we modeled herbimycin exposure as a decrease of 98%
in VSrc values. See Text S1 for details on the parameter estimation
procedure.
The best-fit parameter value for the spontaneous ubiquitylation
was kubBik~0:0036 min
{1. Src-dependent ubiquitylation was
predicted to be inactive in normal fibroblasts as
V
parental
Src ~0 nM:min
{1, which was in agreement with experi-
mental results [5]. On the contrary, the Src pathway was
predominant in transformed cells as VSrc~10:8 nM:min
{1 and
KSrc~671 nM which leads to
VSrc
KSrc
&4:5kub:
The dynamical system 1–2 admits a unique steady state:
½Bik~ 1
2kubBik
(Az
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
A2z4kubBikKSrckfBik
q
)
½Bikub~ kfBik
kdBik
where A~kfBik{kubBikKSrc{VSrc. For parental cells, in which
VSrc is equal to zero, Bik steady state becomes ½BikH~ kfBikkubBik.
Bik steady-state concentrations in parental cells was assumed to
be equal to 50 nM which is in the physiological range of BH3-only
protein intracellular levels [33–37]. This allowed us to deduce
kfBik~0:18 nM:min
{1. We then computed Bik steady-state
concentrations in Src-transformed cells which was equal to
½Bik~9:2 nM. Thus, the simulated ratio of Bik concentration
in Src-transformed cells over that in parental cells was equal to
0.18 which is similar to the experimentally-observed value
quantified to 0.2 (Figure 3, Table 1). This constitutes a partial
validation of the model since the data of Figure 3 was not used in
Bik kinetics model design and calibration. In the following, these
steady state concentrations were used as Bik initial condition since
cells were assumed to be in non-apoptotic conditions prior to the
death stimulus.
Bik kinetics upon apoptotic stress
We then investigated Bik kinetics in parental and Src-
transformed NIH-3T3 cells in response to an apoptotic stress that
consisted of a 8-hour-long exposure to staurosporine (2 mM). As
demonstrated by knockdown experiments (Figure 2b in [5]), Bik
was required for apoptosis induction. Bik was present in non-
transformed cells with no sign of apoptosis in normal conditions,
which suggested either that Bik concentration was not large
enough to trigger apoptosis in these conditions, or that Bik was
activated upon apoptotic stress.
The first assumption to be mathematically investigated was that
Bik protein amount might increase upon staurosporine treatment
as a result of the turning-off of the degradation processes, Bik
synthesis rate remaining unchanged under staurosporine treat-
ment. Thus, if Bik ubiquitylation process is turned off in the model,
only the formation term remains in equation 1 which is now the
same for parental and transformed cells, with different initial
conditions. This equation can be solved analytically:
½Bik(t)~Bik0zkfBikt ð3Þ
where Bik0 stands for Bik initial concentration taken equal to Bik
steady state concentration in parental and transformed fibroblasts.
We did not observe any significant apoptosis either in normal or
Src-transformed cells in the first six hours of staurosporine
treatment (data not shown). In non-transformed cells, setting
t = 360 min in equation 3 gave ½Bik(360)~2:2Bik0 which meant
that Bik concentration would only double in six hours if this
hypothesis was right. This was tested by measuring Bik protein
level during staurosporine exposure in parental cells. However, no
significant increase in Bik levels upon a 6 hour-long staurosporine
treatment was observed, which ruled out that the induction of
apoptosis could depend on Bik accumulation (Figure 4 A).
Therefore, we investigated a second hypothesis that consisted of
an activation of Bik upon apoptosis induction. Such a possibility
might rely on a release of Bik from a protein complex upon
Figure 3. Western blotting analyses of the Bcl-2 family proteins
in control (Ctrl) and v-src-transformed cells (Src). Differential
centrifugation was used for cell fractionation. Each experiment was
repeated at least twice. Mitochondrial Hsp70 and a-tubulin were used
as loading controls for mitochondrial fractions and 10 0006 g
supernatants (10 000 g SN), respectively (loading 100 mg proteins).
Whole cell lysates from HeLa (Bcl-w), BP3 (Bfl1/A1), 293T (Noxa and Bmf)
and WT MEF (Bak) cells were used as positive controls when proteins
were undetected. Data were reprinted with permission from [5].
doi:10.1371/journal.pcbi.1003011.g003
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apoptotic stress as observed with other BH3-only proteins such as
Bad, Bim or Bmf [38]. To investigate the likelihood of this
hypothesis, we performed the immunostaining of endogenous Bik
in parental NIH-3T3 cells upon staurosporine exposure. Our data
was in agreement with a relocation of Bik from its known location
at the ER to the mitochondria within 2 h of treatment ([39,40],
Table 1. Ratios of the different BCL-2 family proteins involved in staurosporine-induced apoptosis.
Parental
cells (nM)
Src-transformed
cells (nM)
Experimentally-determined ratio Src-
transformed/parental
Simulated ratio
Src-transformed/parental
Bik 50 9.2 0.2 0.18
Bax 48 100 2.1 -
Bcl-2+ Bcl-xL +Mcl-1 545 600 1.1 -
Bid 52 40 0.77 -
tBid 1 1 1 -
These values were calculated from the experimental measurements of the Bcl-2 family proteins (Figure 3). See Results section for details.
doi:10.1371/journal.pcbi.1003011.t001
Figure 4. Bik behavior after a death stimulus. A Bik immunoblotting in presence of staurosporine in parental NIH-3T3 cells. Bik protein amount
remained constant during apoptosis. B Bik relocalized from ER to mitochondria during staurosporine exposure in parental NIH-3T3 cells.
Mitochondria were labeled by Mitotracker (red). Endogenous Bik was tracked by an anti-Bik-BH3 and a secondary antibody labeled with FITC (green).
Yellow indicated colocalization.
doi:10.1371/journal.pcbi.1003011.g004
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Figure 4 B). This relocation might correspond to Bik release from a
binding protein at the ER as previously observed [41]. We
modeled this relocation by the equations 4 and 5 in which ½Bikact
stands for Bik protein that had been activated possibly through this
relocation and ½Bik represents inactive Bik molecules. This
translocation occurred at the rate kactBik. Colocalization between
Bik fluorescence and mitotracker staining showed that 45+13% of
Bik molecules were located at the mitochondria within 2 h of
treatment which led to the estimated value kactBik~0:005 min
{1
(Figure 4 B).
Designing a mathematical model of the mitochondrial
pathway of apoptosis in NIH-3T3 fibroblasts
We then investigated the mitochondrial pathway of apoptosis in
NIH-3T3 parental and Src-transformed cells. We only considered
the Bcl-2 members that were experimentally detected in this
biological model [5]. The only pro-apoptotic multidomain effector
was Bax, whereas the multidomain antiapoptotic protein family
was represented by Bcl-2, Bcl-xL and Mcl-1 [5]. Five BH3-only
proteins were present: three BH3-only activators (i.e. able to
directly bind and activate Bax) Puma, Bim and tBid and two BH3-
only sensitizers (i.e. able to bind Bcl-2 and related apoptosis
inhibitors, but unable to bind and activate Bax) Bad and Bik. The
respective role of present BH3-only proteins in apoptosis induction
was assessed by a shRNA-mediated approach.
Bim, which was expressed at very low level, could be neglected
in the onset of apoptosis, since its downregulation induced no
significant increase in apoptosis resistance upon staurosporine,
thapsigargin or etoposide. In contrast, PUMA had a prominent
role for apoptosis induced by genotoxic stresses (UV or etoposide)
but displayed no significant role in staurosporine- and thapsigar-
gin-induced apoptosis [5]. As we focused here on staurosporine-
induced apoptosis, the only BH3-only activator that we considered
was tBid. Concerning BH3-only sensitizers, Bad could be
neglected as its silencing by shRNA did not significantly modify
cell response to staurosporine. Therefore the only sensitizer to be
considered was Bik.
Bax, Bik and tBid were described to bind all the antiapoptotic
proteins expressed in our biological model, namely Bcl2, Bcl-xL
and Mcl-1. Thus, for the sake of simplicity, we denoted by ½Bcl2
the cumulative concentration of those three antiapoptotic proteins.
We thenmodeled Bax activation. In non-apoptotic conditions, Bax
spontaneously adopts a closed 3D-conformation that does not bind
antiapoptotic proteins [10]. This conformation was denoted
½Baxinact. During apoptosis, Bax transforms into an opened 3D-
conformation (½Baxlink) and inserts strongly into theMOM. ½Baxlink
molecules can be inhibited by ½Bcl2 antiapoptotic proteins which
trap them into ½BaxBcl2 dimers. Moreover, they may spontaneously
transform back into their closed conformation ½Baxinact [42].
If they are not inhibited, ½Baxlinkmolecules may oligomerize into
½Baxoligo molecules and create pores in the MOMwhich correlates
with the release into the cytosol of apoptogenic factors, including
cytochrome C [8–10]. We considered that ½Bcl2 was inefficient at
binding oligomerized Bax [7]. In the model, Bax oligomerization
happens either by the oligomerization of two ½Baxlink molecules or
by a much faster autocatalytic process in which a ½Baxoligomolecule
recruits a ½Baxlink molecule to create two ½Baxoligo molecules.
Those two processes occurred at the respective rates kact1 and kact2
which were chosen such that kact2wkact1 to account for the
preponderance of the autocatalytic pathway.
Bax activation from ½Baxinact into ½Baxlink isoforms was
assumed to be catalyzed by the BH3-only activator ½tBid. We
assumed that this reaction occurred in a ‘‘kiss and run’’ manner
and therefore follows Michaelis-Menten kinetics. ½tBid resulted
from ½Bid activation by truncation which occurred at the rate
kfBid [43]. BH3-only activator ½tBid can also be inhibited by
½Bcl2 which trap it into ½tBidBcl2 complexes. Those complexes
may be dissociated by active Bik molecules ½Bikact which bind to
½Bcl2 and release ½tBid [13]. Finally, we also considered that
½Bcl2 antiapoptotic proteins directly inhibit active Bik molecules
and associate into ½BikBcl2 complexes.
Above-mentioned chemical reactions that occur spontaneously
were assumed to follow the law of mass action. All protein
concentrations are expressed in nM in the mathematical model.
This mathematical model is recapitulated in Figure 5 and Table 2.
It can be written as follows:
d½Bik
dt
~{kactBik½Bik ð4Þ
d½Bikact
dt
~kactBik½Bik{kinact2½Bikact½Bcl2{
kfree½Bikact½tBidBcl2
ð5Þ
d½BikBcl2
dt
~kinact2½Bikact½Bcl2zkfree½Bikact½tBidBcl2 ð6Þ
d½Bid
dt
~{kfBH3½Bid ð7Þ
d½tBid
dt
~kfBH3½Bid{kinact3½tBid½Bcl2zkfree½Bikact½tBidBcl2ð8Þ
d½tBidBcl2
dt
~kinact3½tBid½Bcl2{kfree½Bikact½tBidBcl2 ð9Þ
d½Baxinact
dt
~{
Vopen½tBid½Baxinact
Kopenz½Baxinact zkclose½Baxlink ð10Þ
d½Baxlink
dt
~
Vopen½tBid½Baxinact
Kopenz½Baxinact {kclose½Baxlink{kact1½Baxlink
2
{kact2½Baxlink½Baxoligo{kinact1½Baxlink½Bcl2
ð11Þ
d½Baxoligo
dt
~kact1½Baxlink2zkact2½Baxlink½Baxoligo ð12Þ
d½BaxBcl2
dt
~kinact1½Baxlink½Bcl2 ð13Þ
d½Bcl2
dt
~{kinact1½Baxlink½Bcl2{
kinact2½Bikact½Bcl2{kinact3½tBid½Bcl2
ð14Þ
Bik total protein amount was assumed to be constant during
apoptosis as experimentally demonstrated (Figure 4 A). We also
Modeling Src Control on Mitochondrial Apoptosis
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assumed that Bax, Bcl2 and Bid total amounts remained constant
following the death stimulus. However, the apoptotic stress may
induce Bax transcription and repress Bcl2 one, in particular
through the activation of p53 [44]. Four conservation laws hold:
Biktot~½Bikz½Bikactz½BikBcl2
Baxtot~½Baxinactz½Baxlinkz½Baxoligoz½BaxBcl2
Bcl2tot~½Bcl2z½BaxBcl2z½tBidBcl2z½BikBcl2
Bidtot~½Bidz½tBidz½tBidBcl2
Only seven from the eleven equations of the mathematical
model 4–14 need to be solved as the four remaining variables can
be computed using those conservation laws.
We subsequently modeled the cell population behavior. Let us
denote by n(t) the percentage of surviving cells at time t. No cell
division was assumed to occur in presence of staurosporine as the
very first effect of most cytotoxic drug consists in stopping the cell
cycle [45]. Natural cell death was neglected as almost no apoptosis
was observed in either parental or Src-transformed cells in the
Figure 5. Considered molecular pathways of mitochondrial apoptosis. Bik is activated upon death stimulus (Bikact) and inhibits Bcl2
antiapoptotic activity on BH3 activator tBid . Free tBid then activates closed Bax molecules Baxinact into Baxlink which binds to the mitochondrial
membrane. Baxlink molecules then oligomerize with each other (Baxoligo) in an autocatalytic process. Oligomerized Bax molecules create pores in the
mitochondrial membrane which allow the release of apoptogenic factors in the cytosol, leading the cell to apoptosis. Bcl2 also inhibits Baxlink and
Bikact .
doi:10.1371/journal.pcbi.1003011.g005
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absence of death stimuli [5]. We considered that apoptosis is
irreversibly activated when ½Baxoligo concentration reaches the
threshold thres which corresponds to the minimal amount of
oligomerized Bax molecules required to trigger the cytochrome C
release into the cytosol. This assumption was modeled in equation
15 by a S-shape function which also ensures that the death rate
does not grow to infinity. Below is the equation for the percentage
of surviving cells:
dn(t)
dt
~{kapop
½Baxoligoa
½Baxoligoazthresa n(t) ð15Þ
Parameters thres, a and kapop were assumed to be the same for
the two cell populations.
At the initial time just before the apoptotic stress, cells were
assumed to be in steady state conditions. The initial percentage of
surviving cells is n(0)~100%. Bik initial concentrations were set to
steady-state values computed using equations 1–2. Moreover, we
assumed that Bik was entirely under its inactive form so that:
½Bik0~Bik, ½Bikact0~0, ½BikBcl20~0. All Bax molecules are
assumed to be inactive: ½Baxinact0~Baxtot, ½Baxlink0~0 and
½Baxoligo0~0. All existing ½tBid molecules are trapped in
complexes with ½Bcl2: ½tBidBcl20~tBidinit and ½tBid0~0.
Initial protein concentration of Bid and Bcl2 can be computed
using the conservation laws: ½Bid0~Bidtot{tBidinit and
½Bcl20~Bcl2tot{tBidinit. For the sake of simplicity, we consid-
ered that no BaxBcl2 complexes were present at the initial time
(½BaxBcl20~0) as BaxBcl2 dimers do not play any part in the
overall dynamics since we assumed that they do not dissociate.
As previously stated, the considered apoptotic stress consists of
an 8-hour-long exposure to staurosporine (2 mM) which starts at
time t = 0. It triggers two molecular events: ½Bik activation into
½Bikact and ½tBid formation representing ½Bid truncation into
½tBid. Mathematically, kfBH3 and kactBik are set to non-zero
values at the initial time.
Estimating parameters of the mitochondrial apoptosis
model
Parameters of this model of mitochondrial apoptosis were
estimated by fitting experimental data in parental and Src-
transformed cells from [5] and integrating biological results from
literature. First, we assessed quantitative molar values of consid-
ered Bcl-2 family proteins in non-apoptotic conditions as follows.
We set Bax total concentration Baxtot in Src-transformed cells to
100 nM according to [46] in which the authors stated that this was
a physiological level in tumor cells. This value is also in agreement
with concentration ranges found in the literature [33,34,36,47,48].
Then, in [46], they found that anti-apoptotic total concentration
had to be 6 times higher than that of Bax in order to prevent
apoptosis. Therefore, we set Bcl2tot~600nM in Src-transformed
cells. Concerning Bid total concentration, we assumed
Bidtot~40nM which is in agreement with experimental results
from the literature [33,34,36,47]. Finally, tBid initial concentra-
tion tBidinit was set to 1 nM since this band was hardly detectable
by western-blot (Figure 3). Moreover, this value was consistent
with previous modeling results [47].
We then computed protein ratios between parental and Src-
transformed cells using immunoblotting data of Figure 3. We
experimentally determined that there was a 9-fold higher amount
of proteins in the cytosol fraction compared to the mitochondria
compartment which allowed us to compute protein ratios of total
intracellular quantities (Table 1). As previously stated, Bik protein
amount was reduced in Src-transformed cells by a factor of 0.2
compared to parental fibroblasts (Figure 3). This dramatic
decrease was the result of the Src-dependent activation of Erk1/
2 kinases, leading to Bik phosphorylation, polyubiquitylation and
subsequent degradation by the proteasome [5]. Bax steady-state
level in non-apoptotic conditions was increased by a factor of 2.1
in Src-transformed cells compared to normal ones and that of Bid
was decreased by a factor of 0.77. Concerning antiapoptotic
molecules, the sum of Bcl2, Bcl-xL and Mcl-1 quantities was
slightly increased in Src-transformed cells by a factor of 1.1
compared to parental ones. Those protein ratios were used to
compute molar quantities of considered Bcl-2 family protein total
concentrations (Table 1).
Then, we estimated the apoptotic threshold thres as follows.
Quantification of Figure S1d in [5] showed that 38% of BAX
molecules at the mitochondria were activated during apoptosis.
Previously-described quantification of Figure 3 showed that 33%
of BAX total amount were located at the mitochondria, the
remaining part being in the cytosol. Therefore, the percentage of
activated BAX was set to 33% * 38%/100&13%. This percentage
Table 2. Parameters values for the apoptosis model.
No. Reaction Definition Parameter Value
1 Bik?Bikact Bik migration from ER to mitochondria kactBik (min{1) 0.005
2 BikactzBcl2?BikBcl2 Inhibition of Bik by Bcl2 kinact2(nM{1min{1) 0.000105
3 ?tBid tBid formation during apoptosis kfBID(nM:min{1) 0.00014
4 tBidzBcl2?tBidBcl2 Inhibition of tBid by Bcl2 kinact3(nM{1min{1) 0.000087
5 tBidBcl2zBik?tBidzBikBcl2 tBid release from complexes with Bcl2 by Bik kfree(nM{1min{1) 0.88
6 Baxinact ?
tBid
Baxlink
Bax activation by tBid Vopen,Kopen (nM:min
{1,nM) 0.0104, 114
7 BaxlinkzBaxlink?2Baxoligo Oligomerization of two Bax monomers kact1(nM{1min{1) 0.000185
8 BaxlinkzBaxoligo?2Baxoligo Bax autocatalytic oligomerization kact2(nM{1min{1) 0.0144
9 BaxlinkzBcl2?BaxBcl2 Inhibition of Bax by Bcl2 kinact1(nM{1min{1) 0.000021
10 Baxlink?Baxinact Bax spontaneous inactivation kclose(min{1) 0.007
11 Baxoligo?apoptosis Apoptosis triggering by Baxoligo a, kapop(min{1) 4.15, 0.0205
Parameters were fitted to experimental data as described in the Results section and in Text S1.
doi:10.1371/journal.pcbi.1003011.t002
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is in agreement with previous experimental data which suggests
that approximately 10–20% of Bax total amount is actually
activated during apoptosis [46].
The high intensity of the bands corresponding to Bcl-xL
expression in Figure 3 suggested that it might be the predominant
antiapoptotic protein in our biological model. Dissociation constant
between Bcl-xL and respectively Bik, Bid and Bax was experimen-
tally found to be equal to 10 nM, 12 nM and 50 nM [49,50].
Therefore, we set kinact2~
50
10
kinact1 and kinact3~
50
12
kinact1 and only
estimated kinact1. At this point, 10 kinetic parameters still needed to
be estimated.
In order to determine those 10 parameters, we fitted
experimental data from Figure 6 under constraints inferred from
experimental results. We used the three experimental data points
of Figure 6 corresponding to exposure to staurosporine as a single
agent or combined with herbimycin. We modeled the adminis-
tration of staurosporine after an exposure to the Src tyrosine
kinase inhibitor herbimycin as follows. We assumed that
herbimycin was administrated before staurosporine exposure such
that the system had time to reach steady state. As previously
described, herbimycin exposure was modeled by decreasing VSrc
(the maximal velocity of Src-induced Bik ubiquitylation) of 98% of
its original value.
Then, we set constraints on state variables as follows. We
assumed that Baxinact did not decrease below 20% (i.e. the
apoptotic threshold thres) of its initial value within 6 h of
staurosporine exposure as approximately 20% of Bax total
quantity is activated during apoptosis [9,46]. Moreover, we
ensured that Baxoligo reached the apoptotic threshold in parental
cells after 6 to 8 h of exposure to staurosporine as biological
experiments showed. Moreover, as Bax oligomerization was
assumed to be an autocatalytic process, we expected to obtain
kact1vvkact2. Therefore, in the parameter estimation procedure,
we set initial search values for kact1 and kact2 such that
kact1~100kact2. Finally, molecule association rates were searched
between 10{6 and 1 nM{1min{1 which is a realistic range with
respect to the diffusion limit [48]. Estimated parameter values are
shown in Table 2.
The data-fitted mathematical model allowed the investigation of
the dynamical molecular response to staurosporine exposure
(Figure 7). As expected, higher Bik concentration in normal
fibroblasts led to a higher concentration of ½Bikact and of free
½tBid compared to transformed cells. ½tBid molecules then
activated ½Baxinact into ½Baxlink which oligomerized until
reaching the apoptotic threshold in parental cells. On the contrary,
½tBid could efficiently be sequestered in complexes with
antiapoptotic proteins in Src-transformed cells as a result of the
lower level of Bik protein. This perfectly fit the described function
of Bik as a sensitizer [51].
Concerning co-administration of staurosporine and herbymicin,
the model predicted that this drug combination circumvents the
resistance of the cancer cell population in which 99% of cells are
apoptotic after 8 hours of exposure to staurosporine (Figure 6).
This model behavior was in agreement with experimental data
which showed 98% of apoptotic cells in the Src-transformed
population. Moreover, the model predicted that an exposure to
staurosporine as a single agent or combined with herbimycin lead
to the same activity of 80% of apoptotic cells in the parental
fibroblasts population.
Theoretical anticancer therapy optimization and
experimental validation
We intended to determine optimal therapeutic strategies for our
particular biological system in which parental and Src-transformed
NIH-3T3 fibroblasts stand for healthy and cancer cells respec-
tively. In the following, both cell populations are exposed
simultaneously to the same drugs, mimicking the in vivo situation
in which healthy and tumor tissues are a priori exposed to the same
blood concentrations of chemotherapy agents. From a numerical
point of view, identical parameter changes were applied to normal
and cancer cells.
First, we investigated the combination of staurosporine with
ABT-737, a competitive inhibitor of Bcl-2 and Bcl-xL that were
the main antiapoptotic proteins in our cellular model. ABT-737
inhibits free antiapoptotic proteins but also dissociates complexes
of anti- and pro-apoptotic proteins. As for herbimycin, we
Figure 6. Apoptosis in parental (blue) and Src-transformed (orange) NIH-3T3 cells. Bars represent simulations of the calibrated model of
mitochondrial apoptosis. Experimental datapoints for staurosporine given as a single agent or combined with herbimycin were used for parameter
estimation. They are reprinted from [5]. Datapoints for the combination of staurosporine with ABT-737 are original data and were used for model
validation.
doi:10.1371/journal.pcbi.1003011.g006
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assumed that ABT-737 was administrated before staurosporine
such that the system had time to reach steady state. ABT-737 pre-
incubation was thus modeled by decreasing Bcl-2 total amount
Bcl2tot in proportion to ABT-737 concentration and by setting
tBidBcl20~0 and tBid0~tBidtot at the initial time.
Interestingly, ABT-737 exposure in the absence of staurosporine
(i.e. kfBH3~kactBik~0) did not result in cell death induction for
any dose of ABT-737 in the mathematical model, as experimen-
tally demonstrated [5]. Indeed, in the absence of staurosporine,
Bid was not activated into tBid and the low quantity of tBid
present in the cells at steady state was not sufficient to trigger Bax
oligomerization, even when ABT-737 inhibited all anti-apoptotic
proteins. This confirmed that the mathematical model described
correctly this cell model that does not behave as a ‘‘primed for
death model’’ in which inhibition of anti-death proteins results in
death, even in the absence of apoptosis induction. As a reminder,
in the primed for death situation, incubation with ABT-737 led to
cell death as a consequence of the release of the BH3-only
pro-apoptotic proteins that were therefore able to activate Bax.
The main difference between the primed for death situation and
our model is that apoptosis resistance in the primed for death
model primary comes from the overexpression of anti-apoptotic
proteins such as Bcl-xL or Bcl2 that are efficiently inhibited by
ABT-737 whereas here it comes from the decrease of a pro-death
protein in the Src-transformed model.
The combination of staurosporine and ABT-737 at any
concentration, i.e. for any decrease in Bcl2 total protein amount,
was predicted by the model to induce much more apoptosis in
parental cells compared to Src-transformed cells and thus to fail in
circumventing cancer cells resistance (Figure 8). To experimentally
confirm this model prediction, we pre-incubated parental and Src-
transformed cells with ABT-737 prior to staurosporine exposure.
The resulting death-inducing effect on Src-transformed cells was
significantly increased compared to staurosporine alone (Figure 6).
However, as anticipated by the model, this drug combination
resulted in an extremely high toxicity of 99% of apoptotic cells in
Figure 7. Simulated molecular response to staurosporine exposure of parental (blue) and Src-transformed (orange) NIH-3T3 cells.
Higher Bik concentration in normal fibroblasts led to a higher concentration of Bikact and of free tBid . tBid molecules then activated Baxinact into
Baxlink which oligomerized until reaching the apoptotic threshold in control cells but not in Src-transformed cells. Time is expressed in min and
concentrations in nM.
doi:10.1371/journal.pcbi.1003011.g007
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the parental fibroblasts population (Figure 6). Those data points
were reproduced by the calibrated mathematical model for a
predictive decrease of 182 nM in Bcl2 total concentrations in both
cell types.
After that, we looked for theoretically optimal therapeutic
strategies by applying optimization procedures on the calibrated
model of the mitochondrial apoptosis. Optimal strategies were
defined as those which maximized efficacy in cancer cells under
the toxicity constraint that less than 1% of healthy cells die during
drug exposure. We investigated drug combinations that consisted
of the exposure to staurosporine after treatment with Src
inhibitors, or up- or down-regulators of BCL-2 family proteins.
Pre-incubation with inhibitors or activators aimed at modifying
the equilibrium of the biological system before exposure to the
cytotoxic drug. Src inhibition was simulated by a decrease in VSrc
value whereas up- or down-regulation of Bcl-2 family proteins
were modeled by modifying the total concentration of the targeted
proteins.
The theoretically-optimal drug combination would consist of
administering staurosporine combined with inhibitors of Src, Bax
and Bcl2, together with a Bid upregulator. The concentration of
Bax inhibitor should be set such that Bax total concentration
decreases below the apoptotic threshold in healthy cells thus
protecting them from apoptosis. As Bax total amount was higher
in cancer cells, it would remain high enough to allow these cells to
undergo apoptosis. Once healthy cells are sheltered from
apoptosis, Bcl2 amount could be decreased, using for instance
ABT-737, and Bid amount increased at the same time without
risking any severe toxicity. As expected, the optimal therapeutic
strategy also included the suppression of the Src-dependent
phosphorylation of Bik in cancer cells, using for instance
herbimycin. This drug combination led to 99% of apoptotic cells
in the cancer cell population and less than 1% in the parental one
where Bax was hardly present (Figure 9, Text S1).
This theoretically optimal strategy involved the administration
of a cytotoxic agent combined with four other chemicals, which
may not be realistic in the perspective of clinical application.
Therefore we hierarchically ranked the considered therapeutic
agents by searching for optimal strategies consisting in the
combination of staurosporine with only one or two agents.
Strategies which satisfied the tolerability constraint (i.e. less than
1% of apoptotic parental cells) and reached an efficacy value of
99% of apoptotic cells all involved Bax downregulation in addition
to a second agent among Bcl2 downregulator, Bid upregulator
and Src inhibitor (See Text S1 for more details). Of note, isolated
decrease of Bax total amount fulfilled the tolerability constraint but
resulted in less than 1% of apoptotic cancer cells.
Finally, we experimentally validated feasibility of this counter-
intuitive theoretical strategy. We selected two siRNAs that fully
downregulated Bax in parental cells but not in Src-transformed
ones (Figure 10 A). Bax knockdown protected parental cells from
treatment by staurosporine and ABT737 or staurosporine and
herbimycin but not Src-transformed cells (Figure 10 B). Therefore
by downregulating Bax in our biological model, we were capable
of selectively killing Src-transformed cells.
Discussion
A combined mathematical and experimental approach was
undertaken to study the mitochondrial pathway of apoptosis in
parental and Src-transformed NIH-3T3 cells. First, a mathemat-
ical model for Bik kinetics in normal and apoptotic conditions
Figure 8. Simulated cell death after staurosporine exposure and preincubation with ABT-737, in parental (blue) and Src-
transformed (orange) NIH-3T3 cells. Anti-apoptotic inhibitors such as ABT-737 was modeled as a decrease in the amount of Bcl2 molecules. For
any dose of inhibitors, i.e. any decrease of Bcl2 total quantity, simulated apoptosis was greater in parental fibroblasts compared to Src-transformed
cells. Moreover, only the administration of high doses managed to circumvent resistance of transformed cells which also induced an extremely high
toxicity.
doi:10.1371/journal.pcbi.1003011.g008
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was built. It took into account Bik ubiquitylation and further
proteasomal degradation that Src-dependent Bik phosphorylation
stimulated in Src-transformed cells. Then, we designed a
mathematical model of the mitochondrial pathway of apoptosis
which only involved the proteins that participated in apoptosis
induction in the studied biological model. Interestingly, this
mathematical model was quite simple, with only one effector,
Bax, two BH3-only proteins, Bik (a sensitizer) and tBid (a direct
Bax activator), and a pool of antiapoptotic proteins which were
all described as behaving identically toward Bax, Bik and tBid
[38].
Several published works propose mathematical modeling of
apoptosis. Some of them model all pathways to apoptosis from
the death stimulus to the actual cell death [52–54], other focus on
the caspase cascade leading to apoptosis [55]. Molecular
modeling of the mitochondrial pathway was achieved in several
works [47,48,56–59]. Those models being conceived to address
other biological issues, we had to build a new mathematical
model that was tailored to our particular problematic and aimed
at optimizing anticancer therapies in the specific case of Src
transformation.
Exploring Bik kinetics upon apoptosis induction led to the
interesting prediction that the inhibition of Bik degradation might
not allow its accumulation above a threshold that would induce
apoptosis in the experimentally-demonstrated time range. This
was validated by immunoblotting that established that Bik
concentration was not changed upon apoptosis induction by
staurosporine. Therefore, we looked for another explanation that
might support these observations. A possibility was that Bik might
undergo activation upon apoptosis induction. Activation of BH3-
only proteins has already been described and can depend on
phosphorylation/dephosphorylation as observed for Bad or Bim
or on proteolytic activation as for Bid. These post-translational
modifications usually result in a change of cell compartment, from
Figure 9. Simulated molecular response to the optimal therapeutic strategy in parental (blue) and Src-transformed (orange) NIH-
3T3 cells. The optimal strategy consisted of exposing cells to staurosporine after exposure to four chemicals: an Src inhibitor, which annihilates Bik
Src-dependent ubiquitylation in cancer cells, a Bax inhibitor such that Bax quantity is lower than the apoptotic threshold in normal cells, a Bcl2
inhibitor and an agent which enhances Bid transcription. Under this therapeutic strategy, Baxoligo remained under the apoptotic threshold in normal
cells and exceeded it in cancer cells. Time is expressed in min and concentrations in nM.
doi:10.1371/journal.pcbi.1003011.g009
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cytosol to mitochondria for Bad, from cytoskeleton to mitochon-
dria for Bim. Therefore, we looked for a clue pointing towards Bik
activation during apoptosis induction. Indeed, we observed that a
significant part of Bik translocated from the ER, which is its
normal location, to mitochondria upon staurosporine treatment.
This could be due to the release of Bik from a protein complex
with the ER protein GRP78 as described in [41]. However, we
could not rule out that this relocation might also be linked to the
hyperfusion and subsequent mitochondria fission process observed
upon a number of apoptosis stresses [60] or more specifically
associated with Bik [61].
The mathematical model of apoptosis induction was used to
explore anticancer therapies. First, it confirmed that Src inhibitor
circumvented resistance to staurosporine exposure of Src-trans-
formed cells, which was experimentally demonstrated. It also
showed that this therapeutic strategy did not give any specific
advantage to parental cells. It also predicted that inhibitors of
antiapoptotic proteins should not be co-administered with
staurosporine in our particular biological system as a result of
the slightly lower antiapoptotic protein concentration in Src-
transformed cells compared to parental ones. This model
prediction was experimentally validated. Indeed, here, resistance
to apoptosis comes from the decrease in a pro-apoptotic protein in
Src-transformed cells and not from the overexpression of
antiapoptotic proteins as frequently observed, which explains
why a drug inhibiting antiapoptotic proteins could not target
specifically transformed cells.
We then investigated theoretically-optimal therapeutic strate-
gies. Interestingly, all optimal drug combinations took advantage
of the observed Bax overexpression in Src-transformed cells. The
Figure 10. Bax downregulation allowed an advantage to parental cells compared to Src-transformed ones. A Bax was downregulated
in parental (3T3) and Src-transformed (Src) cells using two different siRNAs (see Material & Methods) such that Bax was not detectable anymore in
parental fibroblasts. This was possible since Bax level was higher in transformed cells compared to parental ones (Figure 3) B After Bax
downregulation, parental cells were highly resistance to exposure to staurosporine given as a single agent, combined with ABT-737 or combined
with herbimycin. On the contrary, Src-transformed cells were killed by staurosporine combined with ABT-737 or herbymicin.
doi:10.1371/journal.pcbi.1003011.g010
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optimal therapeutic strategies consisted of the combination of a
cytotoxic agent for the induction of apoptosis (staurosporine in the
model) with Bax downregulator and one agent among Src
inhibitor, Bcl2 inhibitor or tBid upregulator. We experimentally
validated this counterintuitive prediction by demonstrating in our
biological model that Bax knockdown could protect parental cells
but not Src-transformed cells from combinations of staurosporine
with antiapoptotic protein or Src tyrosine kinase inhibitor.
This strategy might be challenging in clinics since siRNA
targeting Bax would need to have the exact same pharmacokinetic
properties as inhibitors of tyrosine kinase or of antiapoptotic
proteins to target all the places where there is expected to be
cytotoxicity. Moreover it would be of importance to also
downregulate Bak, due to redundancy between Bax and Bak
[62]. It would also be of interest to check for Bax/Bak
upregulation in various tumors. Therefore, this study supports
the need for further development of Bax/Bak inhibitors that might
open a therapeutic window for kinase or antiapoptotic protein
inhibitors that would otherwise be globally harmful for the patient
when combined with a cytotoxic treatment.
Materials and Methods
Cell culture and drug exposure
Parental and v-src transformed NIH-3T3 cells were cultured as
described in [5].When indicated, cells were exposed to staurosporine
(2 mM) during 8 hours and pre-incubated overnight with herbimycin
(1 mM) or ABT-737 (1 mM) prior to staurosporine exposure.
Immunoblotting
Immunoblotting was performed as described in [5].
Confocal microscopy
For the analysis of Bik relocalization to mitochondria upon
staurosporine exposure, cells were pre-incubated with Mito-
tracker-red (1:10,000) for 20 min before a 20 min washing in
fresh medium. Then, cells were fixed by addition of paraformal-
dehyde (4%). Mitotracker-red background was removed by a
10 min incubation in acetone at 220uC prior further processing
according to standard procedures. Endogenous Bik was detected
by the specific anti-Bik-BH3 antibody (1:200). The secondary
antibody (Molecular Probe) was labeled with FITC. Nuclei were
stained with Hoechst-33342 dye (1:50,000) in the mounting
medium. Images were acquired by confocal microscopy on a
Axiovert 100 M, LSM510 (Zeiss) using a Plan Apochromat 63x/
1.4 Oil DIC objective. Colocalization of Bik fluorescence and
mitotracker staining was quantified using ImageJ software in 30
single cells treated with staurosporine for 2 h.
Bax downregulation
siBax1 (MMC.RNAI.N007527.12.2) and siBax2 (MMC.RNAI.
N007527.12.4) were purchased from Integrated DNA Technolo-
gies. 100.000 cells were transfected with 10 nM siRNA using
Lipofectamine RNAimax (Life Technologies). 48 h later, cells
were treated overnight either by ABT737 or herbimycin. The day
after, apoptosis was induced by staurosporine treatment (exposure
to 2 mM during 8 hours).
Mathematical modeling and parameter estimation
Matlab ode15s solver was used to solve the systems of ordinary
differential equations. Parameter estimation for Bik kinetics model
consisted of a least-square approach in which minimization tasks
were performed by the CMAES algorithm ([63], Text S1).
Parameter estimation for the mitochondrial apoptosis model
involved the design of a cost function which was also minimized
by the CMAES algorithm. This cost function was the sum of a
Least square term accounting for the fitting of experimental data
of Figure 6 and a term for the constraints described in the Results
section. This term was equal to zero when all constraints were
satisfied and to a thousand times the number of unsatisfied
constraints otherwise [64].
Therapeutics optimization
Optimization procedures for the design of therapeutic strategies
consisted of maximizing efficacy under the constraint of toxicity
not exceeding a tolerability threshold. In order to address this issue
we minimized a cost function which was the sum of two terms.
The first one consisted of the percentage of surviving cells in the
cancer cell population which has to be minimized. The second
term was equal to zero when the toxicity constraint was satisfied
and took a high value (e.g. 1000) otherwise. Minimization tasks
were performed by the CMAES algorithm [63].
Supporting Information
Text S1 This text contains details about parameter estimation of
the Bik kinetics model as well as additional information on
numerical simulations for therapeutics optimization.
(PDF)
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